Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer
Abstract While targeted therapies exist for human epidermal growth factor receptor 2 positive (HER2 +) breast cancer, HER2 + patients do not always respond to therapy. We present the results of utilizing a biophysical mathematical model to predict tumor response for two HER2 + breast cancer patients...
Guardado en:
Autores principales: | Angela M. Jarrett, David A. Hormuth, Vikram Adhikarla, Prativa Sahoo, Daniel Abler, Lusine Tumyan, Daniel Schmolze, Joanne Mortimer, Russell C. Rockne, Thomas E. Yankeelov |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b0d9d0ed140743fbab8a82a362ac28df |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
por: Lize Wang, et al.
Publicado: (2021) -
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
por: Amy S. Clark, et al.
Publicado: (2021) -
Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
por: Phung HT, et al.
Publicado: (2020) -
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Jamunarani Veeraraghavan, et al.
Publicado: (2021) -
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
por: Sara A. Hurvitz, et al.
Publicado: (2020)